Serial Number 79391771
Registration 7504895
700

Registration Progress

Application Filed
Jan 11, 2024
Under Examination
Approved for Publication
Jul 2, 2024
Published for Opposition
Jul 2, 2024
Registered
Sep 17, 2024

Basic Information

Serial Number
79391771
Registration Number
7504895
Filing Date
January 11, 2024
Registration Date
September 17, 2024
Published for Opposition
July 2, 2024
Drawing Code
2

Status Summary

Current Status
Active
Status Code
700
Status Date
Sep 17, 2024
Registration
Registered
Classes
001 005 040 042

Rights Holder

BioInvent International AB

64
Address
Ideongatan 1
SE-223 70 Lund
SE

Ownership History

BioInvent International AB

Original Applicant
64
SE

BioInvent International AB

Owner at Publication
64
SE

BioInvent International AB

Original Registrant
64
SE

Legal Representation

Attorney
Brett A. Manchel

USPTO Deadlines

Next Renewal Deadline
1898 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-09-17)
Due Date
September 17, 2030
Grace Period Ends
March 17, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

29 events
Date Code Type Description
Mar 22, 2025 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 27, 2025 FICS P FINAL DISPOSITION NOTICE SENT TO IB
Feb 26, 2025 FIMP P FINAL DISPOSITION PROCESSED
Dec 20, 2024 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 17, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 17, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER
Jul 8, 2024 GPNX P NOTIFICATION PROCESSED BY IB
Jul 2, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 2, 2024 PUBO A PUBLISHED FOR OPPOSITION
Jun 14, 2024 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 13, 2024 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 12, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 29, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
May 29, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED
May 29, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 29, 2024 GNEA F EXAMINERS AMENDMENT E-MAILED
May 29, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN
May 23, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 23, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
May 23, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
May 9, 2024 RFNT P REFUSAL PROCESSED BY IB
Apr 15, 2024 RFRR P REFUSAL PROCESSED BY MPU
Apr 15, 2024 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 27, 2024 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 26, 2024 CNRT R NON-FINAL ACTION WRITTEN
Mar 26, 2024 DOCK D ASSIGNED TO EXAMINER
Mar 26, 2024 MAFR O APPLICATION FILING RECEIPT MAILED
Mar 22, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 21, 2024 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB

Detailed Classifications

Class 001
Chemicals for use in industry and science; biological preparations for use in industry and science; chemical preparations for analytical and diagnostic purposes and laboratory use, namely, chemical preparations for analytical scientific purposes, chemical diagnostic reagents for scientific use, and chemical substances for analyses in laboratories, other than for medical or veterinary purposes; chemical preparations for use in protein analysis, other than for medical or veterinary purposes; chemicals and chemical preparations for use in the manufacture of pharmaceuticals; chemicals and chemical products for biotechnological purposes, namely, chemicals for use in biotechnological product development; chemical products for immunoassay, namely, immunoassay reagents for non-medical purposes; antibody reagents for scientific purposes; antibodies for scientific purposes, other than for medical or veterinary use.
Class 005
Chemicals for medical purposes, namely, chemical reagents for medical purposes; chemicals for analytical purposes, namely, chemical reagents for medical use; biological preparations for use in cell cultures for medical purposes; antibodies for medical purposes; pharmaceuticals, namely, pharmaceutical preparations for treatment of autoimmune, inflammatory, cardiovascular, infectious, viral, cardiopulmonary, renal, gastrointestinal, respiratory, dermatological, oncological, heptalogical, neurological, musculoskeletal, bacterial, and metabolic diseases and disorders, and pharmaceutical preparations for treatment of cancer
Class 040
Custom manufacturing of antibodies for third parties; custom manufacture of pharmaceuticals
Class 042
Scientific research and development; pharmaceutical product development; consultancy pertaining to pharmacology; research and development services in the field of antibody technology

Additional Information

Design Mark
The mark consists of a design resembling a letter "Y" formed by seven circles.
Pseudo Mark
Y

Classification

International Classes
001 005 040 042